📋 Tender Overview
The DAK-Gesundheit intends to conclude non-exclusive discount agreements for pharmaceuticals under the provisions of § 130a Abs. 8 SGB V. This involves establishing framework discount contracts for medicines that are to be provided at the expense of statutory health insurance. The process will include formal procurement procedures related to the active ingredient Morphine (specifically in the forms FTA + HKP + SMT), ATC N02AA01, with the aim of entering into discount agreements with interested pharmaceutical companies until new agreements come into effect. The contracts will commence on January 1, 2027, and end on December 31, 2028, with an option for a 12-month extension. Morphine (FTA + HKP + SMT)